Korean J healthc assoc Infect Control Prev.  2023 Jun;28(1):42-49. 10.14192/kjicp.2023.28.1.42.

Laboratory Diagnosis of Carbapenemase-producing Enterobacterales

• Kim N
• Hong KH
• Park JS
• Roh KH
• Shin S

• KMID: 2543134
• DOI: http://doi.org/10.14192/kjicp.2023.28.1.42

Abstract

Carbapenem-resistant enterobacterales (CREs) are pathogens of special concern in healthcareassociated infections. Enterobacterales become resistant to carbapenems through several mechanisms, including carbapenemase enzyme production. Enterobacterales that produce carbapenemase are known as carbapenemase-producing enterobacterales (CPEs). Genes encoding carbapenemase are usually found on plasmids that can transmit horizontally between strains, which could explain the rapid spread of carbapenem resistance. Timely and accurate laboratory tests of CPE are necessary to prevent and treat these infections. Various phenotypic tests, such as the modified Hodge test, modified carbapenem inactivation method (mCIM) with or without EDTA-CIM (eCIM), chromogenic agar test, carba NP, immunoassay, mass spectrometry, and molecular tests are available. In this study, we discussed the importance of CRE and CPE control in the COVID-19 pandemic era and summarized several laboratory CPE detection methods currently utilized in clinical microbiology laboratories.

Keyword

Carbapenem-resistant Enterobacterales; Carbapenemase-producing Enterobacterales; Laboratory diagnosis; Phenotypic test; Molecular test

Reference

1. Iredell J, Brown J, Tagg K. 2016; Antibiotic resistance in Enterobacteriaceae: mechanisms and clinical implications. BMJ. 352:h6420. DOI: 10.1136/bmj.h6420. PMID: 26858245.

2. Suay-García B, Pérez-Gracia MT. 2019; Present and future of carbapenem-resistant Enterobacteriaceae (CRE) infections. Antibiotics (Basel). 8:122. DOI: 10.3390/antibiotics8030122. PMID: 31430964. PMCID: PMC6784177.

3. Korean Law Information Center. Infectious Disease Control and Prevention Act, No.18893. https://www.law.go.kr/LSW/eng/engLsSc.do?menuId=2&section=lawNm&query=18893&x=0&y=0. (Updated on 10 June 2022).

4. Kim YH, Kwon D, Lee D. 2020; Reorganization of national notifiable infectious diseases classification system. Public Health Wkly Rep. 13:2–7.

5. KDCA. 2022 Healthcare-associated infectious disease management guideline. https://www.kdca.go.kr/filepath/boardSyview.es?bid=0019&list_no=719403&seq=1. (Updated on 28 April 2022).

6. Adeolu M, Alnajar S, Naushad S, S Gupta R. 2016; Genome-based phylogeny and taxonomy of the 'Enterobacteriales': proposal for Enterobacterales ord. nov. divided into the families Enterobacteriaceae, Erwiniaceae fam. nov., Pectobacteriaceae fam. nov., Yersiniaceae fam. nov., Hafniaceae fam. nov., Morganellaceae fam. nov., and Budviciaceae fam. nov. Int J Syst Evol Microbiol. 66:5575–99. DOI: 10.1099/ijsem.0.001485. PMID: 27620848.

7. Oren A, Garrity GM. 2017; Notification that new names of prokaryotes, new combinations and new taxonomic opinions have appeared in volume 66, part 11, of the IJSEM. Int J Syst Evol Microbiol. 67:179–82. DOI: 10.1099/ijsem.0.001766. PMID: 28287951.

8. KDCA. Notice of amendment of the Infectious Disease Control and Prevention Act. https://opinion.lawmaking.go.kr/gcom/ogLmPp/69053?mappingLbicId=&announceType=. (Updated on 14 July 2022).

9. Lee E, Lee S, Yoon S, Lee Y. 2021; Number of cabapenem-resistant Enterobacteriaceae infections in Republic of Korea (2018-2020). Public Health Wkly Rep. 14:2765–72.

10. Jeong H, Hyun J, Lee Y. 2022; Characteristics of carbapenem-resistant Enterobacteriaceae (CRE) in the Republic of Korea, 2021. Public Health Wkly Rep. 15:2354–63.

11. Ayoub Moubareck C, Hammoudi Halat D. 2022; The collateral effects of COVID-19 pandemic on the status of carbapenemase-producing pathogens. Front Cell Infect Microbiol. 12:823626. DOI: 10.3389/fcimb.2022.823626. PMID: 35372126. PMCID: PMC8968076.

12. Pascale R, Bussini L, Gaibani P, Bovo F, Fornaro G, Lombardo D, et al. 2022; Carbapenem-resistant bacteria in an intensive care unit during the coronavirus disease 2019 (COVID-19) pandemic: a multicenter before-and-after cross-sectional study. Infect Control Hosp Epidemiol. 43:461–6. DOI: 10.1017/ice.2021.144. PMID: 33858547. PMCID: PMC8365044.

13. CLSI. M100 33rd ed. Performance standards for antimicrobial susceptibility testing. https://clsi.org/standards/products/microbiology/documents/m100/(Updated. (Updated on 3 March 2023).

14. Tamma PD, Huang Y, Opene BN, Simner PJ. 2016; Determining the optimal carbapenem MIC that distinguishes carbapenemase-producing and non-carbapenemase-producing carbapenem-resistant Enterobacteriaceae. Antimicrob Agents Chemother. 60:6425–9. DOI: 10.1128/AAC.00838-16. PMID: 27503655. PMCID: PMC5038245.

15. Adelman MW, Bower CW, Grass JE, Ansari UA, Soda EA, See I, et al. 2021; Distinctive features of ertapenem-mono-resistant carbapenem-resistant enterobacterales in the United States: a cohort study. Open Forum Infect Dis. 9:ofab643. DOI: 10.1093/ofid/ofab643. PMID: 35036469. PMCID: PMC8754373.

16. KDCA. Carbapenemase-producing Enterobacteriaceae CPE diagnosis guideline. http://www.icdc.incheon.kr/_lib/fileDownload.php?idx=675. (Updated on 15 December 2014).

17. Cury AP, Andreazzi D, Maffucci M, Caiaffa-Junior HH, Rossi F. 2012; The modified Hodge test is a useful tool for ruling out Klebsiella pneumoniae carbapenemase. Clinics (Sao Paulo). 67:1427–31. DOI: 10.6061/clinics/2012(12)13. PMID: 23295597. PMCID: PMC3521806.

18. Girlich D, Poirel L, Nordmann P. 2012; Value of the modified Hodge test for detection of emerging carbapenemases in Enterobacteriaceae. J Clin Microbiol. 50:477–9. DOI: 10.1128/JCM.05247-11. PMID: 22116154. PMCID: PMC3264163.

19. Ribeiro VB, Linhares AR, Zavascki AP, Barth AL. 2014; Performance of quantification of modified Hodge test: an evaluation with Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae isolates. Biomed Res Int. 2014:139305. DOI: 10.1155/2014/139305. PMID: 24790988. PMCID: PMC3984814.

20. Tsai YM, Wang S, Chiu HC, Kao CY, Wen LL. 2020; Combination of modified carbapenem inactivation method (mCIM) and EDTA-CIM (eCIM) for phenotypic detection of carbapenemase-producing Enterobacteriaceae. BMC Microbiol. 20:315. DOI: 10.1186/s12866-020-02010-3. PMID: 33069233. PMCID: PMC7568406.

21. Sfeir MM, Hayden JA, Fauntleroy KA, Mazur C, Johnson JK, Simner PJ, et al. 2019; EDTA-modified carbapenem inactivation method: a phenotypic method for detecting metallo-β-lactamase-producing Enterobacteriaceae. J Clin Microbiol. 57:e01757–18. DOI: 10.1128/JCM.01757-18. PMID: 30867235. PMCID: PMC6498035.

22. Tamma PD, Simner PJ. 2018; Phenotypic detection of carbapenemase-producing organisms from clinical isolates. J Clin Microbiol. 56:e01140–18. DOI: 10.1128/JCM.01140-18. PMID: 30158194. PMCID: PMC6204673.

23. Cho H, Kim JO, Choi JE, Lee H, Heo W, Cha YJ, et al. 2020; Performance evaluation of automated BD Phoenix NMIC-500 panel for carbapenemase detection in carbapenem-resistant and carbapenem-susceptible Enterobacterales. J Microbiol Methods. 177:106042. DOI: 10.1016/j.mimet.2020.106042. PMID: 32890572.

24. Whitley V, Kircher S, Gill T, Hindler JA, O'Rourke S, Cooper C, et al. 2020; Multicenter evaluation of the BD Phoenix CPO detect test for detection and classification of carbapenemase-producing organisms in clinical isolates. J Clin Microbiol. 58:e01752–19. DOI: 10.1128/JCM.01752-19. PMID: 32132195. PMCID: PMC7180248.

25. Perry JD. 2017; A decade of development of chromogenic culture media for clinical microbiology in an era of molecular diagnostics. Clin Microbiol Rev. 30:449–79. Erratum in: Clin Microbiol Rev 2017;30:vii. DOI: 10.1128/CMR.00097-16. PMID: 28122803. PMCID: PMC5355637.

26. Wilkinson KM, Winstanley TG, Lanyon C, Cummings SP, Raza MW, Perry JD. 2012; Comparison of four chromogenic culture media for carbapenemase-producing Enterobacteriaceae. J Clin Microbiol. 50:3102–4. DOI: 10.1128/JCM.01613-12. PMID: 22760041. PMCID: PMC3421785.

27. Amar M, Shalom O, Adler A. 2017; Comparative evaluation of a new commercial media, the CHROMAgar^TM mSuperCARBA^TM, for the detection of carbapenemase-producing Enterobacteriaceae. Diagn Microbiol Infect Dis. 88:20–2. DOI: 10.1016/j.diagmicrobio.2017.02.004. PMID: 28254249.

28. Dortet L, Agathine A, Naas T, Cuzon G, Poirel L, Nordmann P. 2015; Evaluation of the RAPIDEC® CARBA NP, the Rapid CARB Screen® and the Carba NP test for biochemical detection of carbapenemase-producing Enterobacteriaceae. J Antimicrob Chemother. 70:3014–22. DOI: 10.1093/jac/dkv213. PMID: 26260131.

29. Song W, Yoo G, Hwang GY, Uh Y. 2016; Evaluation of diagnostic performance of RAPIDEC CARBA NP Test for carbapenemase-producing Enterobacteriaceae. Ann Clin Microbiol. 19:59–64. DOI: 10.5145/ACM.2016.19.3.59.

30. Jenkins S, Ledeboer NA, Westblade LF, Burnham CA, Faron ML, Bergman Y, et al. 2020; Evaluation of NG-Test Carba 5 for rapid phenotypic detection and differentiation of five common carbapenemase families: results of a multicenter clinical evaluation. J Clin Microbiol. 58:e00344–20. DOI: 10.1128/JCM.00344-20. PMID: 32376668. PMCID: PMC7315033.

31. Lee S, Hur KH, Chung Y, Sung H, Kim MN. 2021; Evaluation of two commercial kits for rapid detection and typing of carbapenemase in carbapenem-resistant Enterobacterales. Ann Clin Microbiol. 24:45–53. DOI: 10.5145/ACM.2021.24.2.3.

32. Dortet L, Tandé D, de Briel D, Bernabeu S, Lasserre C, Gregorowicz G, et al. 2018; MALDI-TOF for the rapid detection of carbapenemase-producing Enterobacteriaceae: comparison of the commercialized MBT STAR®-Carba IVD Kit with two in-house MALDI-TOF techniques and the RAPIDEC® CARBA NP. J Antimicrob Chemother. 73:2352–9. DOI: 10.1093/jac/dky209. PMID: 29897463.

33. Moore NM, Cantón R, Carretto E, Peterson LR, Sautter RL, Traczewski MM. 2017; Rapid identification of five classes of carbapenem resistance genes directly from rectal swabs by use of the Xpert Carba-R Assay. J Clin Microbiol. 55:2268–75. DOI: 10.1128/JCM.00137-17. PMID: 28515213. PMCID: PMC5483930.

34. Girlich D, Oueslati S, Bernabeu S, Langlois I, Begasse C, Arangia N, et al. 2020; Evaluation of the BD MAX Check-Points CPO Assay for the detection of carbapenemase producers directly from rectal swabs. J Mol Diagn. 22:294–300. DOI: 10.1016/j.jmoldx.2019.10.004. PMID: 31751674.

35. Sawa T, Kooguchi K, Moriyama K. 2020; Molecular diversity of extended-spectrum β-lactamases and carbapenemases, and antimicrobial resistance. J Intensive Care. 8:13. DOI: 10.1186/s40560-020-0429-6. PMID: 32015881. PMCID: PMC6988205.

36. Health Insurance Review & Assessment Service. 2023 National health insurance in Korea. https://repository.hira.or.kr/handle/2019.oak/3076. (Updated on 10 March 2023).

37. Corless CE, Howard AM, Neal TJ. 2020; Impact of different carbapenemase-producing Enterobacterales screening strategies in a hospital setting. Infect Prev Pract. 2:100011. DOI: 10.1016/j.infpip.2019.100011. PMID: 34368706. PMCID: PMC8336178.

38. An J, Lai K, Ma Y, Guo L, Ye L, Luo Y, et al. 2018; Emergence of multiple carbapenemase-producing organisms in single patients: an increasing threat to treatment of infection. J Antimicrob Chemother. 73:544–6. DOI: 10.1093/jac/dkx411. PMID: 29136151.

39. Kang CI. 2022; Antibiotics for multidrug-resistant gram-negative bacteria. J Korean Med Assoc. 65:490–7. DOI: 10.5124/jkma.2022.65.8.490.

40. Garduno A, Martín-Loeches I. 2022; Efficacy and appropriateness of novel antibiotics in response to antimicrobial-resistant gram-negative bacteria in patients with sepsis in the ICU. Expert Rev Anti Infect Ther. 20:513–31. DOI: 10.1080/14787210.2022.1999804. PMID: 34727820.